



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

g1398d

1990 MacArthur Blvd., Ste
Irvine, California 92612-2441
Telephone (949) 798-7600

WARNING LETTER

Certified Mail
Return Receipt Requested

June 15, 2001

Dusan M. Stancic
Managing Director
Central Diagnostic Imaging Network
1220 South Central Avenue; Suite #204
Glendale, CA 91204

W/L Number: 59 - 01
Inspection ID: 2241300001
CFN: 20-32,370
FEI: 3003343674

Dear Dusan Stancic:

We are writing to you because on May 23, 2001, your facility was inspected by a representative of the State of California acting in behalf of the U. S. Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding at your facility:

- Level 1: Processor quality control (QC) records in the month of May 2001 were missing for at least 30% of operating days for the processor described as "MAMMO" (a [redacted] machine, model [redacted]) which is located in the darkroom.

The specific problem noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. This problem is identified as Level 1 because it identifies a failure to meet a significant MQSA requirement.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed

Page Two of Three
June 15, 2001

re: Central Diagnostic Imaging Network
re: Warning Letter Number 59 - 01

Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

In addition, your response should address the Level 2 findings that were listed on the inspection report provided to you at the close of the inspection. These Level 2 findings are:

- Level 2: Failed to produce documents verifying that the radiologic technologist, [REDACTED] (zero [0] continuing education units [CEU's] in 36 months) met the continuing education requirement of having taught or completed at least (fifteen) 15 CEU's in mammography in thirty-six (36) months.

- Level 2: Failed to produce documents verifying that the radiologic technologist, [REDACTED] (ten [10] CEU's in 36 months), met the continuing education requirement of having taught or completed at least fifteen (15) CEU's in mammography in thirty-six (36) months.

- Level 2: Failed to produce documents verifying that the radiologic technologist, [REDACTED] (zero [0] CEU's in 36 months) met the continuing education requirement of having taught or completed at least fifteen (15) CEU's in mammography in thirty-six (36) months.

It is necessary for you to act on this matter immediately. Please explain to this office, in writing, within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations; and
- please provide sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Page Three of Three
June 15, 2001

re: Central Diagnostic Imaging Network
re: Warning Letter Number 59 - 01


Please submit your response to:

Thomas L. Sawyer
Director, Compliance Branch
U.S. Food & Drug Administration
19900 MacArthur Blvd.; Suite #300
Irvine, CA 92612-2445
Phone: (949) 798-7600

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (telephone number 1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Beverly Thomas (MQSA Auditor) at telephone number 949-798-7708.

Sincerely,


Alonza E. Cruse
District Director

cc:

State of California
Dept. of Health Services
Radiological Health Unit
550 South Vermont Avenue; Suite #601
Los Angeles, CA 90020